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Purpose: Cerebral ischemic lesions are frequently observed after carotid artery 
stenting (CAS), and anti-platelet agents are used to prevent stent thrombosis and 
peri-procedural complications. However, despite the premedication, cerebral isch-
emic lesions are observed, suggesting that they may rather be related to anti-plate-
let resistance. We, therefore, investigated the effects of anti-platelet resistance on 
the development of cerebral ischemic lesions after CAS. Materials and Methods: 
We retrospectively reviewed patients who received CAS and selected patients for 
whom brain MRI was performed within 24 hours after CAS and for whom anti-
platelet resistance was checked. Anti-platelet resistance was examined by the Veri-
fyNow system. We analyzed the correlation between anti-platelet resistance and 
cerebral ischemic lesions detected on follow-up MRI. Results: Among 76 pa-
tients, 45 (59.2%) developed new ischemic lesions after CAS. Twelve (15.8%) pa-
tients showed aspirin resistance and 50 (65.8%) patients showed clopidogrel resis-
tance. Patients with a new ischemic lesion demonstrated a significantly greater 
frequency of clopidogrel resistance than those who had no new ischemic lesion 
(82.2% versus 41.9%, p=0.001). The frequency of aspirin resistance was not sig-
nificantly different between the groups of patients with and without new ischemic 
lesions (20.0% versus 9.7%, p=0.340). In multivariate analysis, clopidogrel resis-
tance was a significant risk factor for post-procedural cerebral ischemia. Conclu-
sion: Anti-platelet resistance can be used to predict new ischemic lesions after 
CAS. Anti-platelet resistance should be evaluated in all patients prior to CAS to 
prevent ischemic complications related to CAS.
Key Words:   Cerebral infarction, aspirin resistance, clopidogrel resistance, carotid 
artery stent
INTRODUCTION
Cerebral ischemic lesions are observed by MRI in roughly 50% of patients after 
carotid artery stenting (CAS).1,2 Generally, anti-platelet agents are used as premed-
ication to prevent stent thrombosis and peri-procedural complications.3 Despite pre-
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who took proton pump inhibitors. This study was approved 
by the Severance Hospital Institutional Review Board of 
the Yonsei University Health System in Seoul, Korea.
Carotid artery stent protocol
CAS was performed in patients with symptomatic (ischemic 
stroke or transient ischemic attack related to relevant artery) 
internal carotid artery (ICA) stenosis of 50% or more or as-
ymptomatic stenosis of 70% or more according to the North 
American Symptomatic Carotid Endarterectomy Trial crite-
ria on digital subtraction cerebral angiography. Four experi-
enced neurointerventionist (S.H. Suh, D.J. Kim and B.M. 
Kim in radiology, P.K. Min in cardiology) managed all the 
procedures. We introduced a 90-cm-long 7 F or 8 F guiding 
catheter into the femoral sheath with a 120-cm-long 4 F or 
5 F diagnostic catheter coaxially. Then, we removed the di-
agnostic catheter after appropriate positioning of the guid-
ing catheter proximal to the stenotic lesion.13 We did not 
perform aortogram separately. Pre-stenting balloon angio-
plasty was performed in patients with severe stenosis. In 
cases of difficult penetration of the cerebral protection de-
vice (CPD), balloon angioplasty was initially performed us-
ing a 1.5-2 mm balloon catheter before placement of the 
CPD. After placing the CPD, a self-expandable stent [Pro-
tege (ev3, Irvine, CA, USA), Precise (Cordis endovascular, 
Miami Lakes, FL, USA), or Wallstent (Boston Scientific, 
Natick, MA, USA)] was deployed in the proximal ICA or 
the distal common carotid artery, and post-stenting angio-
plasty was done optionally when residual stenosis (more 
than 50%) was noted on angiography. The patients received 
a bolus injection of 3000-4000 IU heparin just before the 
start of the therapeutic procedure. The time intervals from 
pre-stent MRI to diagnostic cerebral angiography, pre-stent 
MRI to CAS, pre-stent MRI to post-stent MRI and diag-
nostic cerebral angiography to post-stent MRI were deter-
mined for patients who underwent CAS. If one-stage CAS 
was performed, the time interval from the first diagnostic 
angiography to CAS was considered as zero. At least 7 days 
before the procedure, all patients received 75 mg of clopido-
grel and 100 mg of aspirin daily. Neurologic evaluation was 
performed before and at 24 hours after the procedure.
MRI protocol
All MRI examinations were performed on a 3.0T MRI sys-
tem (Signa 3.0T, General Electric, Milwaukee, WI, USA; 
Achieva 3.0T, Philips Medical Systems, Best, the Nether-
lands). Diffusion-weighted images (DWI) were obtained 
medication with aspirin and clopidogrel, however, cerebral 
ischemic lesions are still frequently observed in patients 
upon brain diffusion-weighted MRI.1,2,4-6 Although the clini-
cal implication of these cerebral ischemic lesions after CAS 
is not clear, they could potentially result in focal neurologic 
signs or cognitive dysfunction.1,2,4
Platelet function inhibition by aspirin or clopidogrel dif-
fers from individual to individual, and some patients suffer 
recurrent cerebrovascular or cardiovascular events, regard-
less of proper anti-platelet medication. In these cases, the 
patients may be clinically classified with anti-platelet resis-
tance. A significant proportion of patients with coronary ar-
tery occlusive disease show aspirin or clopidogrel resis-
tance, which is related with major adverse coronary events 
after percutaneous coronary intervention and recurrent ath-
erothrombotic events in patients with acute myocardial in-
farction.7-9 In contrast to coronary artery occlusive disease, 
the role of anti-platelet resistance in carotid artery disease 
has not been well characterized. The reported prevalence of 
aspirin and clopidogrel resistance in cerebrovascular inter-
vention ranges from 2 to 21% for aspirin and 43-52% for 
clopidogrel.10-12 However, these studies included only a few 
CAS patients (6.6%,10 16%,11 33.7%12) and did not provide 
any information about the clinical significance of anti-plate-
let resistance in cerebrovascular stent placement. Therefore, 
we performed this study to determine the clinical signifi-
cance of anti-platelet resistance in patients who underwent 
CAS, by investigating if there was any correlation between 
anti-platelet resistance and new cerebral ischemic lesions 




We retrospectively enrolled 76 patients who satisfied the 
following criteria from January 2007 to May 2011 in our 
registry: premedication of dual anti-platelet agents (aspirin 
and clopidogrel) at least 7 days before CAS, pre-stent brain 
MRI within 60 days, post-stent brain MRI within 24 hours, 
and aspirin and clopidogrel resistance test before CAS or 
within 2 days after CAS. Cases of emergent carotid stent 
insertion, those without pre or post-stent brain MRI, and 
those without anti-platelet resistance tests for both aspirin 
and clopidogrel were excluded. We obtained the past histo-
ry, clinical features, and laboratory findings of patients by 
review of their medical records. We excluded the patients 
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age of the patients was 68.11±7.72 years, and 56 (73.7%) 
patients were males. In total, 39 patients (51.3%) underwent 
one-stage CAS without a previous diagnostic angiography 
procedure. Fifty seven (75.0%) patients had symptomatic 
carotid artery stenosis, 21 (36.8%) patients had a history of 
stroke confirmed by brain CT or MRI and 36 (63.2%) pa-
tients had a transient history of ischemic attack related to the 
carotid stent side within 6 months before CAS. Pre-stent 
balloon angioplasty was performed in 61 (80.3%) patients, 
before placement of the CPD in 7 patients and after place-
ment of the CPD in 54 patients. Seventy patients (92.1%) 
used the CPD. Post-stent balloon angioplasty was performed 
in 47 (61.8%) patients. The mean ARU and PRU values of 
all examined patients were 466.32±79.33 and 257.28±81.84, 
respectively. Twelve (15.8%) patients were resistant to aspi-
rin, while 50 (65.8%) patients were resistant to clopidogrel, 
and 9 (11.8%) patients were resistant to both aspirin and 
clopidogrel. The frequency of aspirin resistance was similar 
to that of resistance to both drugs. 
Among 76 patients, 45 (59.2%) patients had DWI-positive 
lesions; 40 patients were classified with asymptomatic stroke 
and 5 patients with symptomatic stroke. Eleven (24.4%) pa-
tients had a single DWI-positive lesion, 16 (35.6%) patients 
had 2 to 5 lesions, and 18 (40.0%) patients had more than 5 
lesions. In 17 (37.8%) patients, lesions were located only on 
the ipsilateral side to stent placement. In contrast, lesions in 
14 (31.1%) patients were detected in both the ipsilateral and 
non-ipsilateral vascular territory, and lesions in 14 (31.1%) 
patients were detected only in the non-ipsilateral vascular 
territory relative to the CAS. The DWI-positive lesions were 
frequently detected in the cerebral cortex and middle cere-
bral artery (MCA) territory. The DWI-positive lesion size 
was less than 5 mm in 164 (72.8%), 5 mm to 10 mm in 35 
(15.6%) and larger than 10 mm in 26 (11.6%).
All 5 (6.6%) symptomatic stroke cases after the proce-
dure were from the symptomatic carotid artery stenosis 
group and had minor neurological deficits (National Insti-
tutes of Health Stroke Scale score <4). These 5 patients 
were all DWI-positive and demonstrated aspirin and clopi-
dogrel resistance. The location of the lesions according to 
CAS side was the ipsilateral MCA in 3 patients, the bilater-
al MCA in one patient, and the ipsilateral MCA and posteri-
or inferior cerebellar artery in one patient.
In patients with symptomatic carotid stenosis, the time in-
terval between ischemic symptom onset and CAS was 19.69 
days, and there was no time difference between DWI-posi-
tive patients (22.67±20.04 days) and DWI-negative patients 
using the following parameters: TR/TE 9000/81.4 ms, ma-
trix 128×128, FOV 240×240 mm, slice thickness 4 mm, 
b=1000 s/mm2. The resulting voxel volumes were 14 mm3. 
Acute probable ischemic lesions were defined as a hyperin-
tense lesion on DWI or corresponding hypointense lesion 
in apparent diffusion coefficient maps. A pre-stent MRI was 
performed within 60 days before the procedure. Post-stent 
brain DWI was carried out routinely within 24 hours after 
stent placement regardless of the presence of neurologic 
symptoms after CAS. When newly developed lesions were 
found after the procedure by comparing pre- and post-brain 
DWI, the case was defined as DWI-positive. If there were 
no newly developed lesions on follow-up DWI, the case 
was defined as DWI-negative. The number, size and loca-
tion of the DWI-positive lesions according to the vascular 
territory and CAS side were recorded.14
Laboratory examination protocol
All patients received 75 mg of clopidogrel and 100 mg of 
aspirin for at least 7 days before undergoing aspirin and 
clopidogrel resistance tests. Aspirin resistance and clopido-
grel resistance were determined by the VerifyNow system 
(Accumetrics, San Diego, CA, USA). The VerifyNow assay 
is a whole blood, light transmission-based optical detection 
assay that measures platelet aggregation in a cartridge con-
taining fibrinogen-coated beads. An aspirin reaction unit 
(ARU) value ≥550 was defined as aspirin resistance.15 Clop-
idogrel resistance was expressed in P2Y12 reaction units 
(PRU). A PRU value ≥240 was defined as clopidogrel re-
sistance.16 
Statistical analysis
Statistical analyses were performed using PASW Statistics 
18 (IBM, Chicago, IL, USA). Continuous variables are pre-
sented as means with standard deviations and categorical 
variables are presented as frequencies and percentages. Vari-
ables were compared by independent t-test, chi-square test, 
Mann-Whitney U test and Fisher’s exact test. Univariate 
analysis was performed and factors with a p-value less of 
than 0.1 in univariate analysis were included in multivariate 
logistic regression analysis. A two-tailed value of p<0.05 




Seventy-six patients were selected for this study. The mean 
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DISCUSSION
Periprocedural microembolization is an important risk for pa-
tients treated by angioplasty and stent placement of high-
grade carotid stenosis. Atheromatous plaque and superim-
posed thrombi are the main source of microemboli during 
CAS.17 Therefore, anti-platelet premedication and mainte-
nance is very important for preventing peri-procedural isch-
emic events. Recent investigations suggested that anti-platelet 
resistance is associated with cardiovascular or cerebrovascular 
events.9,18,19 Patients with aspirin resistance have been shown 
to have increased mortality and be at greater risk for acute 
coronary syndrome, vascular intervention failure, or new 
cerebrovascular events than aspirin-sensitive patients.18 Fur-
thermore, clopidogrel resistant patients tend to have more 
recurrent cardiovascular events and a higher rate of sub-
acute stent thrombosis after coronary stenting, compared 
(13.89±14.07 days) (p=0.063). For all patients, the duration 
of aspirin and clopidogrel medication before CAS was a 
mean of 11.57 days, and there was also no time difference 
between DWI-positive patients (11.86±4.64 days) and DWI-
negative patients (11.16±2.33 days) (p=0.439). In Spearman 
correlation analysis, there was no correlation between de-
grees of carotid stenosis and ARU (p=0.985, rho=-0.002) or 
PRU (p=0.189, rho=0.152) values.
There was no difference in frequency of aspirin resistance 
between patients with and without DWI-positive lesions 
(p=0.340); however, clopidogrel resistance was detected 
more frequently in patients with DWI-positive lesions than 
patients without (82.2% versus 41.9%, p=0.001) (Table 1). 
After adjusting for age, gender, and degree of stenosis, clop-
idogrel resistance was a significant predictor of DWI-posi-
tive lesions after CAS upon multivariate analysis (odds ra-
tio: 6.804; 95% confidence interval: 2.225-20.806; p=0.001) 
(Table 2). 
Table 1. Comparison of Post Procedural Diffusion Weighted Image Findings 
DWI-negative DWI-positive p value
Demographic data
    Number of patients 31 (40.8) 45 (59.2)
    Sex, male 23 (74.2) 33 (73.3) 0.999
    Age, yrs 68.19±8.99 68.06±6.81 0.944
Interventional factors
    Balloon angioplasty before CPD 1 (3.2)   6 (13.3) 0.230
    Post balloon angioplasty 21 (67.7) 26 (57.8) 0.473
    Use of CPD 29 (93.5) 41 (91.1) 0.999
    Diagnostic angiography to post-stent 
      MRI interval days
5 [2-9] 4 [2-10] 0.467
    Degree of stenosis, % 80.67±8.59 83.26±6.73 0.146
    Symptomatic carotid stenosis 20 (64.5) 37 (82.2) 0.107
Risk factors
    Coronary artery occlusive disease 10 (32.3) 16 (35.6) 0.810
    Hypertension 25 (80.6) 37 (82.2) 0.999
    Diabetes mellitus 11 (35.5) 18 (40.0) 0.811
    Smoking 17 (54.8) 20 (44.4) 0.484
    Previous statin use 25 (80.6) 40 (59.2) 0.340
Laboratory values
    Total cholesterol, mg/dL 176.00±38.40 171.60±39.09 0.647
    HDL cholesterol, mg/dL 44.67±9.92 43.22±9.99 0.546
    LDL cholesterol, mg/dL 102.15±31.92   97.25±32.31 0.544
    Platelets count, ×109/L 239.88±62.56 250.82±66.37 0.463
    Aspirin resistance 3 (9.7)   9 (20.0) 0.340
    Clopidogrel resistance 13 (41.9) 37 (82.2) 0.001
    Fibrinogen, mg/dL 309.63±69.43 286.56±69.28 0.504
    D-dimer, ng/mL   128.67±126.74 153.75±81.12 0.737
DWI, diffusion weighted image; CPD, cerebral protection device; HDL, high density lipoprotein; LDL, low density lipoprotein.
Values are number (%), mean±SD or median [interquartile range].
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considered a very effective tool for detecting acute isch-
emic brain lesions.1,2,4-6,14,23-25 Despite the use of a CPD to 
reduce embolic complications during CAS, post-procedural 
DWI-positive lesions were detected in 15 to 40% of cases 
in previous studies.2,26-29 Firstly, one possible reason for the 
high rate of new ischemic lesions detected after CAS is that 
new lesions may have developed before the stent place-
ment. That is, we cannot exclude the possibility that new 
ischemic lesions developed spontaneously after the index 
stroke or by the time of the first diagnostic cerebral angio-
graphic procedure. However, in our study, about half of the 
patients underwent one stage CAS and there was no differ-
ence in the time interval from pre-stent MRI to diagnostic 
cerebral angiography, pre-stent MRI to CAS, pre-stent MRI 
to post-stent MRI and diagnostic cerebral angiography to 
post-stent MRI between the DWI-positive and negative 
groups. Therefore, the possibility of ischemic lesions not 
related to the CAS itself might not be that high. 
Another possible reason for the high rate of new isch-
emic lesions after CAS in our study may be the use of 3.0T 
MRI; previous studies used 1.5T MRI.1,2,14,27-29 Most impor-
tant difference between 1.5T MRI and 3.0T MRI is the per-
with clopidogrel sensitive patients.9,19 
We investigated the relationship between anti-platelet re-
sistance and the presence of new cerebral ischemic lesions 
that developed after CAS. In our study, 15.8% of patients 
were aspirin resistant and 65.8% were clopidogrel resistant, 
which was comparable to previous studies.10-12 Furthermore, 
the frequency of aspirin resistance was similar to that of re-
sistance to both aspirin and clopidogrel in our study, consis-
tent with a previous report.20 In aspirin resistance patients, 
platelets appear to have increased sensitivity to ADP-induced 
glycoprotein IIb/IIIa activation. These hyper-reactive plate-
lets may be less sensitive to inhibition by clopidogrel.21,22 
In our study, the frequency of clopidogrel resistance was 
significantly higher in DWI-positive patients than in DWI-
negative patients. Therefore, medications which have phar-
macological mechanisms different from that of clopidogrel 
should be considered, if clopidogrel resistance is detected 
in patients with CAS. 
In this study, cerebral ischemic lesions were detected in 
59.2% of patients after CAS, while a CPD was used in 
92.1% of the patients. When performing CAS, cerebral 
ischemic lesions are frequently detected on DWI, which is 
Table 2. Factors for Logistic Analysis for Post Procedural Diffusion Weighted Image-Positive Lesions
Characteristics
Univariate Multivariate
OR (95% CI) p value OR (95% CI) p value
Male 0.957 (0.338-2.709) 0.933 0.586 (0.150-2.287) 0.442
Age (yrs) 0.998 (0.940-1.059) 0.943 0.993 (0.923-1.069) 0.844
Balloon angioplasty before CPD 1.179 (0.351-3.955) 0.790
Post balloon angioplasty 1.535 (0.589-3.998) 0.381
Use of CPD 0.217 (0.025-1.897) 0.167
Diagnostic angiography to post-stent  
  MRI interval days 
1.009 (0.945-1.078) 0.788
Degree of stenosis 1.047 (0.984-1.115) 0.148 1.029 (0.962-1.102) 0.405
Symptomatic carotid stenosis 1.974 (0.630-6.186) 0.243
Coronary artery occlusive disease 1.159 (0.440-3.054) 0.766
Hypertension 1.110 (0.343-3.590) 0.862
Diabetes mellitus 1.212 (0.470-3.125) 0.691
Smoking 0.659 (0.263-1.653) 0.374
Previous statin use 1.920 (0.530-6.959) 0.321
Total cholesterol 0.997 (0.985-1.010) 0.642
HDL cholesterol 0.985 (0.939-1.033) 0.541
LDL cholesterol 0.995 (0.980-1.011) 0.538
Platelets count 0.999 (0.992-1.006) 0.796
Aspirin resistance 2.333 (0.577-9.432) 0.234
Clopidogrel resistance   6.404 (2.251-18.216) 0.001   6.804 (2.225-20.806) 0.001
Fibrinogen 0.997 (0.985-1.009) 0.583
D-dimer 0.996 (0.987-1.005) 0.367
CI, confidence interval; CPD, cerebral protection device; HDL, high density lipoprotein; LDL, low density lipoprotein.
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formance of the gradient subsystem for controlling the 
quality of the DWI. The improved gradient subsystem in 
3.0T MRI allows the voxel size and echo time of the DWI 
sequence to be decreased, thereby increasing resolution. 
This could make 3.0T MRI more accurate for pathologic 
lesion detection than 1.5T MRI, especially when perform-
ing DWI.30 
In our study, minor ischemic strokes occurred in five pa-
tients within 24 hours after CAS. This result was compara-
ble to previous studies, which reported 4.5-7.2% symptom-
atic neurological complication after CAS.2,5,6,23 The fact that 
all of these patients in our study showed resistance to pre-
given anti-platelet agents emphasizes the clinical signifi-
cance of anti-platelet resistance in CAS. 
Our study had several limitations. There was a possibility 
of selection bias, because patients who did not undergo 
post-stent MRI or ant-platelet resistance test were excluded. 
However, we routinely recommended both studies to all pa-
tients with CAS, regardless of patient symptoms or signs af-
ter CAS. In addition, we did not examine the long-term clin-
ical significance of anti-platelet resistance after CAS. These 
limitations are due to retrospective design of the study. 
In conclusion, the evaluation of anti-platelet resistance, es-
pecially clopidogrel resistance, may be useful to predict the 
development of cerebral ischemia after CAS. We, therefore, 
recommend routine check-up of anti-platelet resistance. 
Long-term prospective studies using clinical outcome mea-
surements are needed to clarify the significance of anti-plate-
let resistance in CAS.
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